Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2015

View Archived Issues

Humanized antibodies against pertussis toxin enhance bacterial clearance in baboon model

Accurin nanoformulations improve antitumor activity and PK/PD profile

Cerulean's tunable nanoparticle-drug conjugates are safe and effective antitumor agents

Phase I safety study of bioactive lipid DS-102 completed

Variant licenses worldwide rights to VAR-200 from L&F Research

Janssen starts first-in-human trial of JNJ-64041809 for prostate cancer

Baxalta releases results from pediatric phase III trial of Adynovate

MAPKK inhibitor shows potential for the treatment of cancer cachexia

Pristiq fails to demonstrate superiority over placebo in pediatric patients with MDD

Stemchymal given FDA orphan drug designation for polyglutamine spinocerebellar ataxia

Dicerna advances program for DCR-PH1 in primary hyperoxaluria type 1

Cell therapy improves functional and structural outcome after muscle trauma

MEDI-3039: a potential therapeutic for TNBC

AntibioTx advances preclinical development of dermal formulation of ATx-201

Stemline Therapeutics opens SL-801 IND

Intratumoral injection of EFEMP1-derived tumor suppression protein shows promise for brain cancer

Merck KGaA and Pfizer advance avelumab with two additional phase III trials

ExCellThera cleared to begin phase I/II trial of ECT-100 for expansion of hematopoietic stem cells

Roche makes available new cobas HBV assay for hepatitis B

Biocartis launches assays for BRAF and Ras pathway mutations

Ketogen patents anticonvulsants

EMA accepts Vanda's MAA for Fanaptum

FDA approves AstraZeneca's Zurampic for hyperuricemia in gout

CSL Behring submits MAA for rFVIII-SingleChain to treat hemophilia A

Sanofi files NDA for LixiLan for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...